A staggering $1–2 trillion in economic losses is the price tag for today’s persistent and pervading health care, scientific and medical inequities impacting underrepresented demographics. COVID-19 has peeled back the curtain and highlighted the imperative to identify creative new pathways to close the gap and enhance the participation of marginalized patient populations in clinical trials. RGP’s Marcia Brown-Rayford, VP of Global Head of Life Sciences Research & Development and LaShell Robinson, Director of Diversity and Inclusion in Clinical Trials of Takeda Pharmaceutical, discuss tactical strategies in building trust for patient recruitment, the impact of the digital divide on equity and what role regulatory agencies play in advancing diversity.

To learn how RGP can partner and support your Healthcare needs, visit us: [ Ссылка ]

свернуть